Fluoropyrimidine and platinum-containing chemotherapeutics are used in combination with trastuzumab in HER2-positive GC cases as first-line regimen, while taxanes administered with or without ramucirumab as second-line regimen are routinely used for advanced GC (AGC) treatment [3]; however, such treatments do not remarkably improve prognosis, and median survival is approximately one year [4,5]. Here, ERBB2 is linked to gastric cancer.